<DOC>
	<DOC>NCT01397864</DOC>
	<brief_summary>This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.</brief_summary>
	<brief_title>C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks</brief_title>
	<detailed_description>see below</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH) Patients must give written informed consent A diagnosis of acquired C1INH deficiency (AAE)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>HAE</keyword>
	<keyword>Angioedema</keyword>
	<keyword>Recombinant C1 Inhibitor</keyword>
	<keyword>rhC1INH</keyword>
	<keyword>registry</keyword>
</DOC>